Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

65

Enrollment

OTHER

Sponsor class

Stopped grant and funding expired

Conditions

Breast Atypical Hyperplasia
Breast Lobular Carcinoma in Situ
Breast Atypical Lobular Hyperplasia
Breast Carcinoma

Interventions

DRUG: Tamoxifen
DRUG: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
DRUG: Placebo
OTHER: Questionnaire Administration

Sponsor

Mayo Clinic

Collaborators

[object Object]